Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial-Reference-Cited by-同舟云学术

Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial

Published:2018-09-14 Issue:4 Volume:183 Page:601-607
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Budde Lihua E.¹^ORCID,Wu David²,Martin Daniel B.³,Philip Mary⁴,Shustov Andrei R.⁴,Smith Stephen D.³,Gooley Ted A.³,Chen Tara L.⁴,Libby Edward N.³,Chen Eric Y.⁵,Kojouri Kiarash⁶,Langerak Alan⁷,Roden Jennifer E.⁴,Press Oliver W.³,Gopal Ajay K.³⁴^ORCID

Affiliation:

1. Department of Hematology & Hematopoietic Cell Transplantation; City of Hope; Duarte CA USA

2. Department of Laboratory Medicine; University of Washington; Seattle WA USA

3. Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle WA USA

4. Department of Medicine; Divisions of Medical Oncology and Hematology; University of Washington; Seattle WA USA

5. Group Health Permanente; Seattle WA USA

6. Skagit Valley Hospital Regional Center; Mount Vernon WA USA

7. St. Alphonsus Regional Medical Center; Boise ID USA

Funder

Damon Runyon Cancer Research Foundation

Clinical Investigator Award

National Institutes of Health

Leukemia and Lymphoma Society

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15585/fullpdf

Reference23 articles.

1. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma;Ansell;The New England Journal of Medicine,2015

2. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure;Armand;Journal of Clinical Oncology,2016

3. Cost-comparison analysis of bendamustine, rituximab, etoposide and carboplatin (TREC) vs. RICE/R-DHAP in relapsed lymphoma;Bodding-Long;Journal of Clinical Oncology (ASCO Meeting Abstracts),2015

4. Bendamustine: mechanism of action and clinical data;Cheson;Clinical Advances in Hematology & Oncology: H&O,2011

5. Bendamustine: rebirth of an old drug;Cheson;Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology,2009

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era;Seminars in Hematology;2024-06

2. Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches;Experimental Hematology & Oncology;2022-12-27

3. Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies;Frontiers in Oncology;2021-12-08

4. Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma;Leukemia & Lymphoma;2020-11-04

5. Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma;Cancers;2020-10-08